Nektar Therapeutics (NKTR) Operating Income: 2010-2025
Historic Operating Income for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$31.7 million.
- Nektar Therapeutics' Operating Income rose 7.78% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 35.91%. This contributed to the annual value of -$105.2 million for FY2024, which is 60.10% up from last year.
- Latest data reveals that Nektar Therapeutics reported Operating Income of -$31.7 million as of Q3 2025, which was up 12.58% from -$36.2 million recorded in Q2 2025.
- Nektar Therapeutics' 5-year Operating Income high stood at $14.3 million for Q4 2024, and its period low was -$152.8 million during Q2 2022.
- For the 3-year period, Nektar Therapeutics' Operating Income averaged around -$43.8 million, with its median value being -$36.2 million (2025).
- As far as peak fluctuations go, Nektar Therapeutics' Operating Income slumped by 41.82% in 2021, and later skyrocketed by 142.82% in 2024.
- Nektar Therapeutics' Operating Income (Quarterly) stood at -$112.9 million in 2021, then spiked by 53.53% to -$52.5 million in 2022, then surged by 36.13% to -$33.5 million in 2023, then surged by 142.82% to $14.3 million in 2024, then rose by 7.78% to -$31.7 million in 2025.
- Its Operating Income was -$31.7 million in Q3 2025, compared to -$36.2 million in Q2 2025 and -$44.5 million in Q1 2025.